Dynamics of device innovation: Implications for assessing value

International Journal of Technology Assessment in Health Care

Volumn 29, Issue 4, 2013, Pages 365-373

  Gelijns, Annetine C ^a   Russo, Mark J ^b   Hong, Kimberly N ^a   Brown, Lawrence D ^a,c   Ascheim, Deborah D ^a   Moskowitz, Alan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Barnabas Health   (United States)

^c Department of Health Policy and Management Mailman School of Public Health Columbia University ^*  (United States)

Author keywords

Medical devices; Value purchasing

Indexed keywords

COST EFFECTIVENESS; LEFT VENTRICULAR ASSIST DEVICES;

ANALYTIC APPROACH; COST EFFECTIVENESS ANALYSIS; COST EFFECTIVENESS RATIO; DESTINATION THERAPY; ECONOMIC IMPACTS; MEDICAL DEVICES; MOVING TARGETS; POLICY MAKING;

COST BENEFIT ANALYSIS;

ANTICOAGULATION; ARTICLE; BLOOD RESERVOIR; CARDIOVASCULAR MORTALITY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DEVICE SAFETY; EXTRACELLULAR MATRIX; HEALTH CARE COST; HEALTH CARE POLICY; HEART ATRIUM FIBRILLATION; HEART OUTPUT; HEART TRANSPLANTATION; HEART VENTRICLE CONTRACTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MEDICAL DECISION MAKING; MEDICAL INFORMATICS; MEDICARE; MEDICATION COMPLIANCE; PATIENT PREFERENCE; PUBLIC-PRIVATE PARTNERSHIP; QUALITY OF LIFE; TRANSCATHETER AORTIC VALVE IMPLANTATION; UNCERTAINTY; BIOMEDICAL TECHNOLOGY ASSESSMENT; DEVICE APPROVAL; ECONOMICS; HEART ASSIST DEVICE; HEART LEFT VENTRICLE FUNCTION; INVENTION; PROCEDURES; PURCHASING; THERAPY;

DEVICE APPROVAL; HEART-ASSIST DEVICES; INVENTIONS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; VALUE-BASED PURCHASING; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84889575887     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462313000561     Document Type: Article

References (47)

1. Porter ME. What is value in health care? N Engl J Med. 2010;363:2477-2481.
2. Gelijns AC, Killelea B, Vitale M, Mankad V,Moskowitz AJ. The dynamics of pediatric device innovation: Putting evidence in context. In: Safe medical devices for children. Washington, DC: Institute of Medicine, National Academy Press; 2006:302-326.
3. Gelijns AC, Rosenberg N. The dynamics of technological change in medicine. Health Aff (Millwood). 1994;13:28-46.
4. Drummond M, Griffin A, Tarricone R. Economic evaluation for devices and drugs-same or different? Value Health. 2009;12:402-404.
5. Sorenson C, Tarricone R, Siebert M, Drummond M. Applying healTheconomics for policy decision making: Do devices differ from drugs? Europace. 2011;13(Suppl 2):ii54-ii58.
6. Taylor RS, Iglesias CP. Assessing the clinical and cost-effectiveness of medical devices and drugs: Are they that different? Value Health. 2009;12:404-406.
7. Ernst & Young. Pulse of the IndustryMedical Technology Report 2012.-http://www.ey.com/Publication/vwLUAssets/Pulse-medical-technology-report- 2012/$FILE/Pulse-medical-technology-report-2012.pdf (accessed July 23, 2013).
8. Kirisits A, Redekop WK. The economic evaluation of medical devices: Challenges ahead. Appl HealThecon Health Policy. 2013;11:15-26.
9. US Food and Drug Administration. Medical devices. 2012 Monthly PMA Listings. http://www.fda.gov/MedicalDevices/ProductsandMedical Procedures/DeviceApprovalsandClearances/PMAApprovals/ucm295841. htm (accessed July 23, 2013).
10. US Food and Drug Administration. Medical devices. 2012 Medical Device 510(k) Clearances. http://www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/DeviceApprovalsandClearances/510k Clearances/ucm289685.htm (accessed July 23, 2013).
11. Hulstaert F, Neyt M, Vinck I, et al. Pre-market clinical evaluations of innovative high-risk medical devices in Europe. Int J Technol Assess Health Care. 2012;28:278-284.
12. Dhruva SS, Bero LA, Redberg RF. The strength of study evidence examined by the FDA in pre-market approval of cardiovascular devices. JAMA. 2009;302:2679-2685.
13. Chen CE,Dhruva SS, Redberg RF. Inclusion of comparative effectiveness data in high-risk cardiovascular device studies at the time of premarket approval. JAMA. 2012;308:1740-1742.
14. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435-1443.
15. National Coverage Determinations Manual. http://www.cms.gov/Regulations- and-Guidance/Guidance/Transmittals/downloads/R2NCD1. pdf (accessed July 23, 2013). 16.
16. Parides MK, Moskowitz AJ, Ascheim DD, Rose EA, Gelijns AC. Progress versus precision: Challenges in clinical trial design for left ventricular assist devices. Ann Thorac Surg. 2006;82:1140-1146.
17. National Institute for Health Care Management, (NIHCM). Changing patterns of pharmaceutical innovation 2002. http://nihcm.org/pdf/innovations.pdf (accessed July 23, 2013).
18. Dowling RD, Park SJ, Pagani FD, et al. HeartMate VE LVAS design enhancements and its impact on device reliability. Eur J Cardiothorac Surg. 2004;25:958-963.
19. Alli OO, Booker JD, Lennon RJ, et al. Transcatheter aortic valve implantation. Assessing the learning curve. JACC Cardiovasc Interv. 2012;5:72-79.
20. Lange R, Bleiziffer S, Mazzitelli D, et al. Improvements in transcatheter aortic valve implantation outcomes in lower surgical risk patients. A glimpse into the future. J Am Coll Cardiol. 2012;59:280-287.
21. Pisano GP, Bohmer R, Edmondson AC. Organizational differences in rates of learning: Evidence from the adoption of minimally invasive cardiac surgery. Manage Sci. 2001;47:752-768.
22. Holzhey DM, Seeburger J, Misfeld M, Borger MA, Mohr FW. Learning minimally invasive mitral valve surgery: A cumulative sum sequential probability analysis of 3895 operations from a single high-volume center. Circulation. 2013;128:483-491.
23. Rosenberg N. Inside the black box: Technology and economics. Cambridge: Cambridge University Press; 1983
24. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: Implications for patient selection. Circulation. 2007;116:497-505.
25. Cowger J, Sundareswaran K, Rogers JG, et al. Predicting survival in patients receiving continuous flow left ventricular assist devices: The HeartMate II risk score. J Am Coll Cardiol. 2013;61:313-321.
26. Gregoric I, Wadia Y, Radovancevic B, et al. HeartMate vented-electric left ventricular assist system: Technique for intrathoracic or intraperitoneal implantation via a left thoracotomy. J Heart Lung Transplant. 2004;23:759-762.
27. Pasque MK, Hanselman T, Shelton K, Hedges R, Keohe-Huck B. Operative strategies to reduce complications in Novacor left ventricular assist device placement. J Card Surg. 2004;19:329-335.
28. Wagner F, Buz S, Neumeyer HH, Hetzer R, Hocher B, Nitric oxide inhalation modulates endothelin-1 plasma concentration gradients following left ventricular assist device implantation. J Cardiovasc Pharmacol. 2004;44(Suppl 1):S89-S91.
29. Holdy K, Dembitsky W, Eaton LL, et al. Nutrition assessment and management of left ventricular assist device patients. J Heart Lung Transplant. 2005;24:1690-1696.
30. Dang NC, Naka Y. Perioperative pharmacotherapy in patients with left ventricular assist devices. Drugs Aging. 2004;21:993-1012.
31. Holman WL, Rayburn BK, McGiffin DC, et al. Infection in ventricular assist devices: Prevention and treatment. Ann Thorac Surg. 2003;75(Suppl):S48- S57.
32. Zietkiewicz M, GarlickiM, Domaga?a J, et al. Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device. J Thorac Cardiovasc Surg. 2002;123:384-385.
33. Miller LW, Nelson KE, Bostic RR, et al. Hospital costs for left ventricular assist devices for destination therapy lower costs for implantation in the post-REMATCH era. J Heart Lung Transplant. 2006;25:778-784.
34. Pagani FD, Long JW, Dembitsky WP, Joyce LD, Miller LW. Improved mechanical reliability of the HeartMate XVE left ventricular assist system. Ann Thorac Surg. 2006;82:1413-1418.
35. Long JW, Healy AH, Rasmusson BY, et al. Improving outcomes with long-term "destination" therapy using left ventricular assist devices. J Thorac Cardiovasc Surg. 2008;135:1353-1360.
36. Slaughter MS, Sobieski MA, Gallagher C, Dia M, Silver MA. Low incidence of neurologic events during long-term support with the Heart-Mate XVE left ventricular assist device. Tex Heart Inst J. 2008;35:245-249.
37. Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison ofMedical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:2311-2321.
38. Yao G, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28:42-51.
39. Pagani FD,Miller LW, Russell SD, et al. Extendedmechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312-321.
40. Boyle A, Teuteberg J, Ascheim DD, et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by preoperative INTERMACS classification. J Heart Lung Transplant. 2011;30: 402-407.
41. Kirklin JK, Naftel DC, Kormos RL, et al. Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant. 2013;32:141-156.
42. Slaughter MS, Rogers JG, Milano CA, et al. HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.
43. Park SJ, Milano CA, Tatooles AJ, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5:241-248.
44. Ascheim DD, Gelijns AC, Rose EA. Innovation wiThexperience using implantable left ventricular assist devices. Circ Heart Fail. 2009;2:1-2.
45. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'coverage wiThevidence development'. Health Aff (Millwood). 2006;25:1218-1230.
46. Campbell B. NICE medical technology guidance: Devices and diagnostics. Heart. 2011;97:1794-1795.
47. Campbell B. The NICE Medical Technologies Advisory Committee and medical technologies guidance. Heart. 2011;97:674-675.